Literature DB >> 9013281

The soluble interleukin-2 receptor, peripheral blood, and reticulocyte fractions in acute pancreatitis.

T Salomone1, P Boni, C Serra, A M Morselli-Labate, A L Di Gioia, M Romboli, A Guariento.   

Abstract

CONCLUSION: In acute pancreatitis (AP), the peripheral blood analysis, including reticulocytes (RC) and RC fractions, and its relationship to the changes of the levels of the soluble interleukin 2 receptor (sIL-2R) can provide useful information about the involvement of the immunoinflammatory system in AP and can indicate the severity of the disease.
BACKGROUND: In the disease clinical assessment, we correlated the sIL-2R serum levels to the peripheral blood components (including RC and RC fractions) to serum albumin and C-reactive protein (CRP) during AP.
METHODS: In 21 patients with AP, sIL-2R, the total and differential white blood cell (WBC) counts, red blood cell (RBC) counts, RC, RC fractions, hemoglobin (Hb), hematocrit (Ht), platelets (PLT), albumin, and CRP were evaluated from the onset to the sixth day of illness.
RESULTS: sIL-2R increased in all the patients. The increase was directly related to eosinophils, monocytes, and to middle-aged (MFR) RC, and inversely related to neutrophils and the old (LFR) RC. MFR-RC were directly related to the total WBC count, eosinophils, and basophils, and inversely related to Hb and albumin. LFR-RC behaved in the opposite manner. CRP increased in 16 patients; this rise was directly related to WBC, RC, and MFR-RC, and inversely related to Hb, LFR-RC, and albumin. sIL-2R and CRP values were not statistically interrelated, but when the CRP levels were higher, the increase in sIL-2R was greater and more sustained.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013281     DOI: 10.1007/BF02803769

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  9 in total

Review 1.  Cytokines in inflammatory bowel disease.

Authors:  J Brynskov; O H Nielsen; I Ahnfelt-Rønne; K Bendtzen
Journal:  Scand J Gastroenterol       Date:  1992-11       Impact factor: 2.423

2.  Prognostic signs and the role of operative management in acute pancreatitis.

Authors:  J H Ranson; K M Rifkind; D F Roses; S D Fink; K Eng; F C Spencer
Journal:  Surg Gynecol Obstet       Date:  1974-07

Review 3.  Lowest dose interleukin-2 immunotherapy.

Authors:  K A Smith
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

Review 4.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

5.  High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.

Authors:  D Maraninchi; D Blaise; P Viens; M Brandely; D Olive; M Lopez; D Sainty; G Marit; A M Stoppa; J Reiffers
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

6.  Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A.

Authors:  J A Viedma; M Pérez-Mateo; J E Domínguez; F Carballo
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

7.  Inflammatory response in the early prediction of severity in human acute pancreatitis.

Authors:  J A Viedma; M Pérez-Mateo; J Agulló; J E Domínguez; F Carballo
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

8.  Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis.

Authors:  D I Heath; A Cruickshank; M Gudgeon; A Jehanli; A Shenkin; C W Imrie
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

9.  Behavior of serum soluble interleukin-2 receptor, soluble CD8 and soluble CD4 in the early phases of acute pancreatitis.

Authors:  R Pezzilli; P Billi; L Gullo; E Beltrandi; M Maldini; R Mancini; L Incorvaia; M Miglioli
Journal:  Digestion       Date:  1994       Impact factor: 3.216

  9 in total
  1 in total

1.  Effects of time interval for hemofiltration on the prognosis of severe acute pancreatitis.

Authors:  En-Qiang Mao; Yao-Qing Tang; Sheng-Dao Zhang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.